RALB

Across TCGA pan-cancer cohorts, RALB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RALB data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RALB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RALB expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where RALB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.260	0.842	.001	49	view →
PDAC	DFS	Quartile	All	0.569	0.827	<.001	46	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.780	.009	15	view →
UCEC	DFS	Tertile	All	0.826	0.979	.028	4	view →
LSCC	DFS	Median	II,III,IV	0.801	0.557	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RALB–LUAD (OS)

Open the LUAD breakdown →